Merck & Co. (MRK)
(Delayed Data from NYSE)
$131.20 USD
+0.48 (0.37%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $131.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Earnings News For MRK
-
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
-
Merck: Q1 Earnings Snapshot
-
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
-
Merck (MRK) Reports Next Week: Wall Street Expects Earnings Growth
-
Merck (MRK) Beats Q4 Earnings Estimates
-
Merck: Q4 Earnings Snapshot
-
Merck (MRK) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
-
Can Merck (MRK) Keep the Beat Streak Alive in Q4 Earnings?
-
Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales
-
Merck (MRK) Q3 Earnings and Revenues Beat Estimates
-
Merck: Q3 Earnings Snapshot
-
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
-
Merck (MRK) Reports Next Week: Wall Street Expects Earnings Growth
-
Why Is Merck (MRK) Up 4.3% Since Last Earnings Report?
-
Merck (MRK) Beats on Q2 Earnings and Sales, Ups 2023 View
-
Merck (MRK) Reports Q2 Loss, Tops Revenue Estimates
-
Merck: Q2 Earnings Snapshot
-
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
-
Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for
-
Merck (MRK) Beats on Q1 Earnings and Sales, Ups 2023 View
-
Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates
-
Merck: Q1 Earnings Snapshot
-
Merck (MRK) to Report Q1 Earnings: What's in the Cards?
-
Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for
-
Merck (MRK) Beats on Q4 Earnings & Sales, 2023 View Disappoints